Media coverage about Shire PLC (NASDAQ:SHPG) has been trending somewhat positive recently, Accern reports. Accern rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Shire PLC earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.1732526233875 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news articles that may have impacted Accern’s analysis:

Shire PLC (SHPG) traded down 0.91% on Friday, hitting $148.61. 958,069 shares of the company were exchanged. The stock has a 50 day moving average of $164.82 and a 200 day moving average of $172.65. Shire PLC has a 52 week low of $147.79 and a 52 week high of $209.22. The company has a market capitalization of $44.26 billion, a price-to-earnings ratio of 66.49 and a beta of 1.60.

Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.53 by $0.20. The firm had revenue of $3.75 billion during the quarter. Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. Shire PLC’s revenue for the quarter was up 54.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.38 EPS. Analysts predict that Shire PLC will post $14.93 EPS for the current fiscal year.

The business also recently declared a semiannual dividend, which will be paid on Friday, October 20th. Stockholders of record on Friday, September 8th will be given a $0.1527 dividend. This represents a dividend yield of 0.21%. The ex-dividend date is Thursday, September 7th. Shire PLC’s dividend payout ratio is presently 40.63%.

Several research firms recently commented on SHPG. Cantor Fitzgerald set a $222.00 target price on shares of Shire PLC and gave the stock a “buy” rating in a research report on Saturday, July 1st. Barclays PLC downgraded shares of Shire PLC from an “overweight” rating to an “equal weight” rating in a research report on Friday. Jefferies Group LLC reiterated a “hold” rating and set a $206.00 target price (down from $216.00) on shares of Shire PLC in a research report on Wednesday. BidaskClub downgraded shares of Shire PLC from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Finally, Zacks Investment Research upgraded shares of Shire PLC from a “sell” rating to a “hold” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $222.27.

COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Insider Buying and Selling by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.